The first Norwegian CAR
Made in Oslo by a team of researchers from Oslo University Hospital, the first ever Norwegian CAR T cell is now a fact. A potential treatment based on this result depends on a clinical study.
The CAR (Chimeric Antigen Receptor) construct was designed, manufactured and validated in two laboratories in the Radium Hospital campus. One is headed by Else Marit Inderberg and Sébastien Wälchli and the other is led by June Helen Myklebust and Erlend B. Smeland.
Links:
Article about the findings published on the Oslo Cancer Cluster home page:
The first Norwegian CAR
The article published in Blood Advances:
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S.
Blood Adv. 2019 Apr 23;3(8):1230-1243. doi: 10.1182/bloodadvances.2018029678.
PMID: 30979721
Research group home pages:
At the Section of Cellular Therapy, under the Department of Oncology:
- Immunomonitoring Unit and Translational Research, headed by Else Marit Inderberg
- Translational research, headed by Else Marit Inderberg and Sébastien Wälchli
At the Department of Cancer Immunology, under the Institute for Cancer Research:
- Lymphoma Biology, headed by June M. Myklebust and Erlend B. Smeland